The Evidence Pack: How Deramiocel's Five-Year Data is Reshaping Duchenne Muscular Dystrophy Treatment

For boys and young men living with Duchenne muscular dystrophy (DMD), the progression of the disease follows a cruel and predictable timeline. As the genetic lack of dystrophin causes skeletal muscles to waste away, patients typically lose the ability to walk by their early teens.[7]

In the later stages of the disease, the clinical battleground shifts. The focus of care moves to preserving the function of the upper limbs—which dictate a patient's ability to feed themselves and operate a wheelchair—and protecting the heart, as cardiac complications have become the leading cause of mortality in DMD.[3][7]

Until now, few therapies have shown the ability to meaningfully alter this late-stage trajectory across both skeletal and cardiac muscle. But landmark five-year data presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference in Orlando, Florida, suggests a paradigm shift is underway.[1][5]

The data centers on deramiocel (formerly known as CAP-1002), an investigational cell therapy developed by Capricor Therapeutics. According to the newly released results from the HOPE-2 Open-Label Extension (OLE) study, deramiocel provides durable, long-term preservation of both upper limb and heart function.[1][4]

"Together, these five-year OLE data and our HOPE-3 Phase 3 results represent the totality of our clinical evidence for deramiocel, and they tell a consistent story," Capricor CEO Dr. Linda Marbán stated, emphasizing the therapy's sustained benefit and favorable safety profile.[1]

To understand why deramiocel is generating such optimism, it is necessary to look at its unique mechanism of action. Unlike gene therapies that attempt to deliver a functional dystrophin gene, deramiocel is an allogeneic cell therapy composed of cardiosphere-derived cells (CDCs).[2][3]

These CDCs are isolated from healthy human heart tissue. However, the cells themselves do not permanently engraft into the patient's muscle. Instead, they act as microscopic factories, secreting extracellular vesicles known as exosomes.[1][2]

These exosomes are packed with RNA and proteins that exert potent immunomodulatory and anti-fibrotic effects. In DMD, chronic inflammation drives the replacement of healthy muscle tissue with rigid, non-functional scar tissue. Deramiocel's exosomes target macrophages—key immune cells—and reprogram them from a pro-inflammatory state to a tissue-healing phenotype.[1][3]

The clinical translation of this mechanism is most evident in the skeletal muscle data. In the HOPE-2 OLE study, researchers measured upper limb function using the Performance of the Upper Limb (PUL 2.0) scale, a validated metric for assessing independence in DMD.[1][4]

Over the five-year period, the nine patients remaining in the extension study experienced a mean total-score decline of less than 5 points on the PUL 2.0 scale.[1][4]

To contextualize this, researchers compared the results to a cohort-matched external control group receiving standard-of-care treatment. The standard-of-care group showed a modeled decline of approximately 2.4 points per year—which projects to a devastating 12-point loss over five years. By attenuating this decline to roughly 1 point per year, deramiocel effectively preserved years of upper-body independence.[1][4]

Equally critical is the therapy's impact on the heart. As DMD patients live longer due to better respiratory care, DMD-associated cardiomyopathy has emerged as the primary threat to survival.[2][3]

In the HOPE-2 OLE study, cardiac function was measured by left ventricular ejection fraction (LVEF) using cardiac MRI. Remarkably, LVEF remained stable over the entire five-year period for patients treated with deramiocel.[1][5]

In stark contrast, a propensity-matched external cardiac comparator demonstrated a modeled decline in LVEF of approximately 3.2% per year. Furthermore, data from the broader Phase 3 HOPE-3 trial showed that deramiocel significantly reduced the progression of myocardial scar tissue, providing the first clinical evidence that the therapy's anti-fibrotic effects directly benefit the human heart.[1][2]

Safety remains a paramount concern for any long-term biologic therapy. Across the clinical development program, deramiocel has been administered via intravenous infusion over 800 times. The five-year data confirmed a consistently favorable safety profile, with no new safety signals or imbalances in severe adverse events compared to placebo groups in the controlled trials.[1][4]

The totality of this evidence now sits before the U.S. Food and Drug Administration (FDA). Capricor's Biologics License Application (BLA) is currently under active review, with a Prescription Drug User Fee Act (PDUFA) target action date set for August 22, 2026.[2][4]

The regulatory path includes a crucial milestone: the FDA has scheduled an advisory committee meeting for July 29, 2026, where independent experts will publicly weigh the HOPE-2 extension and HOPE-3 Phase 3 data.[6]

If approved, deramiocel would become the first cell-based therapy authorized specifically for DMD cardiomyopathy, and the first to explicitly target the dual skeletal and cardiac dysfunction that defines the disease's later stages.[2]

For the Duchenne community, the prospect of a therapy that can stabilize the heart and preserve the ability to use a wheelchair joystick, feed oneself, or embrace a family member represents a profound shift in what is medically possible.[7]